Thu Sep 19 06:11:29 UTC 2024: ## Vincerx Pharma Stock Dips Despite Beating Earnings Estimates

**New York, NY – September 19, 2024** – Vincerx Pharma, Inc. (NASDAQ: VINC) saw its stock price decline by 2.1% on Wednesday, closing at $0.69. This follows the company’s recent earnings report, which saw them exceed analyst expectations for the quarter ending August 8th.

Vincerx Pharma, a clinical-stage biopharmaceutical company focused on cancer treatment, reported earnings per share of ($0.05), beating the consensus estimate of ($0.17) by a significant margin. Analysts are currently forecasting a loss of $0.49 per share for the full year.

Despite the positive earnings news, trading volume for Vincerx Pharma was significantly lower than average, suggesting a lack of investor interest. The company’s stock has been volatile in recent months, with its 50-day moving average sitting at $0.68 and its 200-day moving average at $1.69.

Vincerx Pharma is currently developing two key treatments: enitociclib, a cyclin-dependent kinase-9 inhibitor for hematologic malignancies, and VIP236, a small molecule drug conjugate for solid tumors. Both treatments are currently in Phase 1 clinical trials.

The company’s market capitalization stands at $20.41 million, with a P/E ratio of -0.38 and a beta of 1.51.

**To stay up-to-date on Vincerx Pharma news and analyst ratings, sign up for MarketBeat.com’s FREE daily email newsletter.**

Read More